Uptravi
by Johnson & Johnson
Uptravi (selexipag) is prescribed for adults with pulmonary arterial hypertension (PAH)—high blood pressure in the arteries of the lungs. It primarily affects the small pulmonary arterioles. PAH is al...
Uptravi (selexipag) is prescribed for adults with pulmonary arterial hypertension (PAH)—high blood pressure in the arteries of the lungs. It primarily affects the small pulmonary arterioles. PAH is also known as Group 1 pulmonary hypertension. Uptravi can slow disease progression and prevent PAH-related hospitalizations.
Uptravi tablets come in a variety of strengths from 200 to 1600 micrograms. Patients typically are started on the lowest dose, taking 1 200-microgram tablet twice daily, in the morning and again in the afternoon.
During the initial adjustment phase, your healthcare professional will titrate your dose upward until you reach the optimum therapeutic level. That’s the level that provides the greatest benefit without triggering unpleasant side effects.
Uptavi can also be administered as an intravenous infusion by a healthcare professional.
Patient assistance programs
Uptravi Patient Assistance Program
Manufacturer PAP- Eligibility
- Patients who meet income and insurance requirements
- Income limit
- Varies — contact ClariMeds for current limits
- Insurance
- Typically uninsured or underinsured; Medicare/Medicaid restrictions may apply
- How to apply
- Apply through ClariMeds — we handle the paperwork at no cost
Need help applying?
ClariMeds handles the entire application process for you — for free. See if you qualify in minutes.
See If You Qualify — Free